Martin H. Stradner, Christian Dejaco, Kerstin Brickmann, Winfried B. Graninger and Hans Peter BrezinschekEmail authorView ORCID ID profile
Arthritis Research & Therapy201618:190
DOI: 10.1186/s13075-016-1091-1© The Author(s). 2016
Received: 14 May 2016Accepted: 8 August 2016Published: 24 August 2016
Although B cell depletion with rituximab (RTX) is an effective treatment strategy in rheumatoid arthritis (RA), one third of patients do not achieve remission or low disease activity (LDA). Thus, identifying patients who will benefit from RTX is highly desirable. In the present study we investigated whether lymphocyte subsets other than B cells are predictors of a clinical response to RTX treatment.
Patients with RA who were receiving RTX for the first time were included in an observatory registry. Clinical assessments, complete blood count and flow cytometry of lymphocyte subsets were obtained at baseline and at week 24 after RTX. Complete data were available for 44 patients. Logistic regression and receiver operating characteristic curve analyses were computed to analyze the predictive value of lymphocyte subsets for European League Against Rheumatism (EULAR) response and LDA (defined as disease activity score in 28 joints (DAS28) ≤3.2) at week 24.
EULAR responders had lower total lymphocyte counts (LC), T cells and CD4 + T cells at baseline. Although these parameters were independent predictors of EULAR response they failed in determining who would reach LDA. In contrast, LC >2910/μl or plasmablast frequency >2.85 % at baseline predicted a significantly higher DAS28 at week 24 after RTX and identified patients not achieving LDA at week 24 with sensitivity of 93.3 % and specificity of 44.8 %.
A combination of LC and plasmablast frequency identifies patients with RA who will not benefit from RTX with high probability.
Rheumatoid arthritis Biomarker Rituximab T cells Plasmablasts Lymphocytes